Trost A, Motloch K, Bruckner D, Schroedl F, Bogner B, Kaser-Eichberger A, Runge C, Strohmaier C, Klein B, Aigner L, Reitsamer H A
University Clinic of Ophthalmology and Optometry, Research Program for Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University/SALK, 5020 Salzburg, Austria; Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
University Clinic of Ophthalmology and Optometry, Research Program for Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University/SALK, 5020 Salzburg, Austria.
Exp Eye Res. 2015 Jul;136:59-71. doi: 10.1016/j.exer.2015.05.010. Epub 2015 May 20.
Glaucoma is a group of neurodegenerative diseases characterized by the progressive loss of retinal ganglion cells (RGCs) and their axons, and is the second leading cause of blindness worldwide. Elevated intraocular pressure is a well known risk factor for the development of glaucomatous optic neuropathy and pharmacological or surgical lowering of intraocular pressure represents a standard procedure in glaucoma treatment. However, the treatment options are limited and although lowering of intraocular pressure impedes disease progression, glaucoma cannot be cured by the currently available therapy concepts. In an acute short-term ocular hypertension model in rat, we characterize RGC loss, but also microglial cell activation and vascular alterations of the retina at certain time points. The combination of these three parameters might facilitate a better evaluation of the disease progression, and could further serve as a new model to test novel treatment strategies at certain time points. Acute ocular hypertension (OHT) was induced by the injection of magnetic microbeads into the rat anterior chamber angle (n = 22) with magnetic position control, leading to constant elevation of IOP. At certain time points post injection (4d, 7d, 10d, 14d and 21d), RGC loss, microglial activation, and microvascular pericyte (PC) coverage was analyzed using immunohistochemistry with corresponding specific markers (Brn3a, Iba1, NG2). Additionally, the tightness of the retinal vasculature was determined via injections of Texas Red labeled dextran (10 kDa) and subsequently analyzed for vascular leakage. For documentation, confocal laser-scanning microscopy was used, followed by cell counts, capillary length measurements and morphological and statistical analysis. The injection of magnetic microbeads led to a progressive loss of RGCs at the five time points investigated (20.07%, 29.52%, 41.80%, 61.40% and 76.57%). Microglial cells increased in number and displayed an activated morphology, as revealed by Iba1-positive cell number (150.23%, 175%, 429.25%,486.72% and 544.78%) and particle size analysis (205.49%, 203.37%, 412.84%, 333.37% and 299.77%) compared to contralateral control eyes. Pericyte coverage (NG2-positive PC/mm) displayed a significant reduction after 7d of OHT in central, and after 7d and 10d in peripheral retina. Despite these alterations, the tightness of the retinal vasculature remained unaltered at 14 and 21 days after OHT induction. While vascular tightness was unchanged in the course of OHT, a progressive loss of RGCs and activation of microglial cells was detected. Since a significant loss in RGCs was observed already at day 4 of experimental glaucoma, and since activated microglia peaked at day 10, we determined a time frame of 7-14 days after MB injection as potential optimum to study glaucoma mechanisms in this model.
青光眼是一组神经退行性疾病,其特征是视网膜神经节细胞(RGCs)及其轴突逐渐丧失,是全球第二大致盲原因。眼压升高是青光眼性视神经病变发展的一个众所周知的危险因素,药物或手术降低眼压是青光眼治疗的标准程序。然而,治疗选择有限,尽管降低眼压可阻碍疾病进展,但目前可用的治疗方案无法治愈青光眼。在大鼠急性短期高眼压模型中,我们在特定时间点对RGC丧失、小胶质细胞激活和视网膜血管改变进行了表征。这三个参数的组合可能有助于更好地评估疾病进展,并可进一步作为在特定时间点测试新治疗策略的新模型。通过在大鼠前房角注射磁性微珠(n = 22)并进行磁性位置控制来诱导急性高眼压(OHT),导致眼压持续升高。在注射后的特定时间点(4天、7天、10天、14天和21天),使用相应的特异性标记物(Brn3a、Iba1、NG2)通过免疫组织化学分析RGC丧失、小胶质细胞激活和微血管周细胞(PC)覆盖情况。此外,通过注射德克萨斯红标记的葡聚糖(10 kDa)来确定视网膜血管的紧密性,随后分析血管渗漏情况。为了记录,使用共聚焦激光扫描显微镜,随后进行细胞计数、毛细血管长度测量以及形态学和统计学分析。在研究的五个时间点,磁性微珠注射导致RGC逐渐丧失(分别为20.07%、29.52%、41.80%、61.40%和76.57%)。与对侧对照眼相比,小胶质细胞数量增加并呈现激活形态,这通过Iba1阳性细胞数量(分别为150.23%、175%、429.25%、486.72%和544.78%)和颗粒大小分析(分别为205.49%、203.37%、412.84%、333.37%和299.77%)得以体现。OHT 7天后,中央视网膜的周细胞覆盖(NG2阳性PC/mm)显著减少,外周视网膜在OHT 7天和10天后显著减少。尽管有这些改变,但在OHT诱导后14天和21天,视网膜血管的紧密性保持不变。虽然在OHT过程中血管紧密性未改变,但检测到RGC逐渐丧失和小胶质细胞激活。由于在实验性青光眼第4天就观察到RGC显著丧失,且激活的小胶质细胞在第10天达到峰值,我们确定在注射微珠后7 - 14天这个时间段作为在该模型中研究青光眼机制的潜在最佳时间框架。